Company Profile

Dr. Reddy's is currently trading at Rs. 5223.95, up by 84.75 points or 1.65% from its previous closing of Rs. 5139.20 on the BSE.

The scrip opened at Rs. 5189.00 and has touched a high and low of Rs. 5260.55 and Rs. 5056.00 respectively. So far 79906 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5514.65 on 21-Sep-2020 and a 52 week low of Rs. 2497.60 on 19-Mar-2020.

Last one week high and low of the scrip stood at Rs. 5514.65 and Rs. 4411.50 respectively. The current market cap of the company is Rs. 84593.04 crore.

The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.97% and 15.25% respectively.

Dr Reddy's Laboratories has settled a litigation with a unit of Bristol Myers Squibb related to patents for Revlimid (lenalidomide) capsules, used to treat various kinds of cancer. The Hyderabad-based company has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb.

In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a license to sell volume-limited amounts of generic lenalidomide capsules in the US beginning on a confidential date after March 2022 subject to regulatory approval, it added. The agreed-upon percentages are confidential.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr Reddy's Laboratories has settled a litigation with a unit of Bristol Myers Squibb related to patents for Revlimid (lenalidomide) capsules, used to treat various kinds of cancer. The Hyderabad-based company has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb.

In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a license to sell volume-limited amounts of generic lenalidomide capsules in the US beginning on a confidential date after March 2022 subject to regulatory approval, it added. The agreed-upon percentages are confidential.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Laboratories is currently trading at Rs. 5014.45, up by 187.85 points or 3.89% from its previous closing of Rs. 4826.60 on the BSE.

The scrip opened at Rs. 5001.00 and has touched a high and low of Rs. 5023.00 and Rs. 4951.05 respectively. So far 33305 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5,023.00 on 18-Sep-2020 and a 52 week low of Rs. 2497.60 on 19-Mar-2020.

Last one week high and low of the scrip stood at Rs. 5023.00 and Rs. 4336.85 respectively. The current market cap of the company is Rs. 80244.64 crore.

The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.97% and 15.25% respectively.

Dr Reddy's Laboratories has settled a litigation with a unit of Bristol Myers Squibb related to patents for Revlimid (lenalidomide) capsules, used to treat various kinds of cancer. The Hyderabad-based company has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb.

In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a license to sell volume-limited amounts of generic lenalidomide capsules in the US beginning on a confidential date after March 2022 subject to regulatory approval, it added. The agreed-upon percentages are confidential.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

TVS Motor Company has entered into a new distribution partnership with Autotecnica Colombiana SAS (Auteco SAS), a leading motorcycle assembler in Colombia. Autotecnica Colombiana SAS will operate 50 dealerships exclusive to TVS Motor and create dedicated space for the brand in over 600 retail outlets. They will support TVS Motor with dedicated sales, service, spares and customer relationship management (CRM). Autotecnica Colombiana SAS will also provide the brand with an assembly set-up in Cartagena along with a dedicated training centre.

Sterling and Wilson Solar has signed an order of 106.71 MW worth $62.6 million (Rs 462 crore) in Chile. The order has been received from a global independent power producer (IPP), work for which is expected to begin in Q4 FY 2021. The company already has a strong presence in the region with one project of 93.3 MW in Argentina and three projects of 588 MW under construction in Chile.

Hindalco Industries has entered into a memorandum of understanding (MoU) with Hindustan Copper (HCL) for the long-term purchase and sale of copper concentrate produced by the PSU. Under this MoU, around 60 percent copper content of HCL’s current copper concentrate production will be utilised by Hindalco in the manufacture of refined copper. Hindalco’s copper is used by key industries, such as power, electronics, railways and construction.

Hindustan Zinc is planning to offer rated, unsecured, redeemable, non-cumulative, non-convertible debentures (NCDs) aggregating up to Rs 4,000 crore in one or more tranches, and in this regard is holding a meeting of its duly constituted Committee of the Directors on September 22, 2020. The said issuance is pursuant to the approval of the board of directors in its meeting held on July 21, 2020.

Dr Reddy's Laboratories has settled a litigation with a unit of Bristol Myers Squibb related to patents for Revlimid (lenalidomide) capsules, used to treat various kinds of cancer. The Hyderabad-based company has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb. In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a license to sell volume-limited amounts of generic lenalidomide capsules in the US beginning on a confidential date after March 2022 subject to regulatory approval, it added. The agreed-upon percentages are confidential.

Brooks Laboratories has entered into joint venture partnership with SteriScience. The global marketing joint-venture arrangement, shall focus on international markets such as USA, Europe and other regulated markets. Simultaneously the joint venture partners have also entered into manufacturing joint venture towards building a robust carbapenem business with integrated manufacturing capabilities, subject to approval from the shareholders of Brooks. This is a landmark value-accretive partnership, which furthers Brooks' global aspirations.

PTC India Financial Services (PFS) has received Rs 115.57 crore from Income Tax Department as IT refund for Assessment Year (AY) 2019-20 (Financial Year 2018-19). The company may utilize the amount of refund received in financing sustainable environmental friendly infrastructure projects related to green energy, water sewage treatment plan, electric vehicle charging station etc.

Dr. Reddy's Laboratories, along with its subsidiaries have launched over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalents of Pataday Once Daily Relief and Pataday Twice Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).  Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.

This launch marks the entry of Dr. Reddy’s into the OTC eye care space, and is a testament to deep capabilities in bringing store-brand equivalents of Rx-to-OTC switches to the U.S. market. The Pataday brand had U.S. sales of approximately $31 million since the launch in March 2020.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.